Introduction

iOnctura, a biopharmaceutical company that is at the clinical stage and is also focusing on precision oncology, revealed that its C.E.O., Catherine Pickering, is going to give a presentation at the 44th Annual J.P. Morgan Healthcare Conference. The conference will be held from January 12 to 15, 2026, in the city of San Francisco, California.

Catherine's presentation not only represents but also signifies the importance of the company as it keeps pushing the envelope with its compound of small-molecule therapies that are specifically designed to target cancers that are neglected and hard to treat.

Event Details

• Conference: Annual J.P. Morgan Healthcare Conference 44th Edition

 

• Venue: San Francisco, California

 

• Date and Time (Tuesday, January 18, 2028, at 10 a.m. MT)

 

Speaker: Catherine Pickering, CEO and co-founder of iOnctura

The J.P. Morgan Healthcare Conference is often regarded as the most important investor gathering of the biotechnology and pharmaceutical sectors. It unites the world's innovators, investors, and partner companies to share the latest views on the market, the latest breakthroughs in clinics, and the largest upcoming opportunities to be strategized over.

 

iOnctura's participation in this gathering demonstrates its rising recognition and the global health community's growing interest in its precision oncology programs.

 

Focus on Roginolisib and Clinical Progress

During the conference, Catherine Pickering will present the company’s clinical advancement particularly in the area of roginolisib, which is the leading drug candidate of iOnctura.

Roginolisib is characterized as:

 

• The first allosteric modulator of PI3Kδ

 

• Precision oral small molecule

 

• Being clinically tested in multiple Phase II studies for solid and hematologic cancers

 

The drug molecule employs a novel non-ATP competitive mechanism that seeks to selectively inhibit the PI3Kδ signaling pathway. This pathway is often aberrantly activated in multiple types of cancers. Promising indications of clinical activity have been uncovered during the first-phase trials, including the prolongation of overall survival in rare cancer patients, when compared with historical records.

 

Clinical Program and Trials

Ongoing clinical studies of iOnctura consist of:

 

• OCULE-01 for eye melanoma (started on March 2025)

 

• PULMO-01 in lung cancer (non-small cell NSCLC) (started on May 2025)

 

• HEMA-MED Phase I/II in myelofibrosis (started on November 2025)

 

The above-mentioned trials are being conducted by iOnctura with the aim to assess roginolisib in various types of cancers and not just one, thus trying to get through with its safety and efficacy to larger patient populations.

 

Company Background and Investor Interest

Founded to address the issue of neglected cancers, iOnctura is based in Amsterdam, The Netherlands, with additional sites in Geneva, Switzerland, and Cambridge, Massachusetts, USA.

This company also enjoys the support of a consortium of expert institutional investors, such as Syncona, M Ventures, Inkef Capital, EIC Fund, VI Partners, Schroders Capital, and XGEN Venture, which highlights the substantial financial backing for its pioneering research portfolio.

The executives of iOnctura will be present at the conference and open for private discussions with investors and strategic partners about the future vision and plans of the company.